Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.

Breast (Edinburgh, Scotland) - 1 Feb 2020

Romero Sally A D, Su H Irene, Satagopan Jaya, Li Q Susan, Seluzicki Christina M, Dries Annika, DeMichele Angela M, Mao Jun J

Abstract excerpt

BACKGROUND: Arthralgia is a common and debilitating toxicity of aromatase inhibitors (AI) that leads to premature drug discontinuation. We sought to evaluate the clinical and genetic risk factors associated with AI-associated arthralgia (AIAA). METHODS: We performed a cross-sectional study among postmenopausal women with stage 0-III breast cancer who were prescribed a third-generation AI for adjuvant therapy. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthralgia

Share to Breast Neoplasms

Share to Cross-Sectional Studies

Share to Genetic Markers

Share to Logistic Models

Share to Postmenopause

Source

Open in PubMed Open full text

Identifiers

PMID: 31678641
DOI: 10.1016/j.breast.2019.10.008
PMCID: PMC7375589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.PMID 31678641Read ↗

Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.Semantic proximity Read ↗

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.Semantic proximity Read ↗

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.Semantic proximity Read ↗

Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.Semantic proximity Read ↗

Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm.Semantic proximity Read ↗

Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.Semantic proximity Read ↗

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.Semantic proximity Read ↗

Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.Semantic proximity Read ↗

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.Semantic proximity Read ↗

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.Semantic proximity Read ↗

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.Semantic proximity Read ↗

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.